ESR1 and breast cancer: In our present study, in which we start with an analysis of the response of MCF7-LTED cells to different small compounds and then report our testing of predictions in different cohorts of breast cancer patients, we propose that VAV3/VAV3 is a key ERα-downstream determinant of the response to endocrine therapies.